201 related articles for article (PubMed ID: 28034547)
1. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?
Ataca Atilla P; Bakanay Ozturk SM; Demirer T
Transfus Apher Sci; 2017 Apr; 56(2):190-198. PubMed ID: 28034547
[TBL] [Abstract][Full Text] [Related]
2. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
Goker H; Etgul S; Buyukasik Y
Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
[TBL] [Abstract][Full Text] [Related]
3. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
4. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
[TBL] [Abstract][Full Text] [Related]
7. European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.
Worel N; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Hübel K; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Duarte RF; Mohty M
Transfusion; 2012 Nov; 52(11):2395-400. PubMed ID: 22414093
[TBL] [Abstract][Full Text] [Related]
8. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
Jantunen E; Varmavuo V
Expert Opin Biol Ther; 2014 Jun; 14(6):851-61. PubMed ID: 24673120
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
14. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.
Avramova BE; Yordanova MN; Konstantinov DN; Bobev DG
Drug Des Devel Ther; 2011; 5():407-9. PubMed ID: 21966213
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34
Imoto N; Kondo Y; Uchida K; Kurahashi S
Intern Med; 2024 Jan; 63(2):189-195. PubMed ID: 37225486
[TBL] [Abstract][Full Text] [Related]
16. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality.
Azzouqa AM; Jouni K; Roy V; Zubair AC
J Clin Apher; 2019 Feb; 34(1):39-43. PubMed ID: 30426567
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Tichopád A; Vítová V; Kořístek Z; Lysák D
J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
[TBL] [Abstract][Full Text] [Related]
18. Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G; Vanazzi A; Radice D; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Lanza F; Lemoli RM; Olivieri A; Laszlo D; Martino M; Specchia G; Pavone V; Imola M; Pasini A; Milone G; Scortechini I; Todisco E; Guggiari E; Cascavilla N; Martinelli G; Rambaldi A; Bosi A
Transfusion; 2014 Feb; 54(2):331-9. PubMed ID: 23781769
[TBL] [Abstract][Full Text] [Related]
20. Advances in mobilization for the optimization of autologous stem cell transplantation.
Vose JM; Ho AD; Coiffier B; Corradini P; Khouri I; Sureda A; Van Besien K; Dipersio J
Leuk Lymphoma; 2009 Sep; 50(9):1412-21. PubMed ID: 19603345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
